



*DFW*

Attorney Docket No. VPI/03-152 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/821,663  
Confirmation No.: 8789  
Filing Date: April 9, 2004  
Examiner: Not Yet Assigned  
Group art unit: 1614  
Applicants: Cottrell et al.  
For: INHIBITORS OF SERINE PROTEASES, PARTICULARLY HVC NS3-NS4A  
PROTEASE

February 9, 2005  
Cambridge, Massachusetts

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT**

(a) Pursuant to Rule 56, it is requested that the documents listed on the accompanying 1449 form be considered and made of record in the above-identified patent application. Copy(ies) of references B1-B3 are attached.

- (b) ☒ No fee is believed due because:
- ☐ The Information Disclosure Statement is being filed within three (3) months of the filing date of the application.
  - ☐ The Information Disclosure Statement is being concurrently filed with the above-identified application.
  - ☐ The Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).
  - ☒ The Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.
- (c) ☐ The Information Disclosure Statement is being filed before the mailing date of any final action, notice of allowance or an action that otherwise closes prosecution; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

Applicants: Cottrell et al.  
Application No.: 10/821,663

- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- (d) ☐ The Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- ☐ No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement; and
- ☐ The Director is hereby authorized to charge \$180.00 to Deposit Account No. 50-0725.
- ☒ The Director is hereby authorized to charge any additional fees that may be required for the Information Disclosure Statement, or credit any overpayment to Deposit Account No. 50-0725. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,



Michael C. Badia, Reg. No. 51,424  
Agent for Applicants  
c/o Vertex Pharmaceuticals Incorporated  
130 Waverly Street  
Cambridge, Massachusetts 02139  
Tel: (617) 444-6467  
Fax: (617) 444-6483

Our Docket No.: VPI/03-152 US



**Certificate Of Mailing Under 37 CFR §1.8**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On February 9, 2005.  
Date

1. Information Disclosure Statement (3 pages, in duplicate);
2. PTO-1449 Form (1 page, in duplicate);
3. Cited References (B1-3); and
4. This Return Postcard Receipt.

A handwritten signature in cursive script, appearing to read "Karen DiRocco", written over a horizontal line.

Signature

Karen DiRocco

Typed or printed name of person signing Certificate



Modified Form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	<b>Application Number</b>	10/821,663
	<b>Filing Date</b>	April 9, 2004
	<b>First Named Inventor</b>	Kevin M. Cottrell
	<b>Group Art Unit</b>	1614
	<b>Examiner Name</b>	Not Yet Assigned
	<b>Attorney Docket Number</b>	VPI/03-152 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO	03/006490	Vertex Pharmaceuticals, Inc.	23 January 2003		
	B2	WO	03/087092	Vertex Pharmaceuticals, Inc.	23 October 2003		
	B3	WO	98/17679	Vertex Pharmaceuticals, Inc.	30 April 1998		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.